<DOC>
	<DOC>NCT01697462</DOC>
	<brief_summary>This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. Patients will be followed until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Metastatic colorectal cancer Receiving Xeloda according to registered indication Patients who are not eligible for Xeloda treatment according to the Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>